Search

Objective To investigate the noninvasive indicators of indications for antiviral therapy in HBeAg - negative chronic hepatitis B virus (HBV) infection patients with alanine aminotransferase (ALT)=40 U/ L under the guidance of liver pathology. Methods A retrospective analysis was performed for the clinical data of 377 HBeAg - negative chronic HBV infection patients with ALT =40 U/ L who were hospitalized in Affiliated Hospital of Yan’an University, from October 2013 to August 2018 and underwent liver biopsy, among whom the patients with inflammatory activity < A2 and fibrosis stage < F2 were enrolled as non - antiviral therapy group(n =266), and the patients with inflammatory activity =A2 or fibrosis stage =F2 were enrolled as antiviral therapy group(n =111). The chi - square test was used for comparison of categorical data between two groups;the t - test was used for comparison of normally distributed continuous data between two groups, and the Mann - Whitney U test was used for comparison of non - normally distributed continuous data between two groups;univariate and multivariate binary logistic regression analyses were used to screen out the influencing factors for the initiation of antiviral therapy;the receiver operating characteristic (ROC) curve was plotted to evaluate the diagnostic efficiency of each indicator in determining the need for antiviral therapy in HBeAg - negative chronic HBV infection patients with ALT =40 U/ L. Results Of all 377 patients, 266 (70. 6% )did not need antiviral therapy for the time being, and 111 (29. 4% )had marked liver damage and thus needed active antiviral therapy. The multivariate analysis showed that liver stiffness measurement (LSM) (odds ratio [HR]=2. 003, 95% confidence interval [CI]:1. 647 - 2. 437, P <0.05), HBsAg (HR =1. 563, 95% CI:1. 110 -2. 200, P <0. 05), HBV DNA (HR =1. 519, 95% CI:1.173 -1. 966, P < 0. 05), and albumin (HR =0. 939, 95% CI:0. 884 -0. 998, P <0. 05)were independent influencing factors for the initiation of antiviral therapy. The ROC curve analysis showed that the area under the ROC curve (AUC)was 0. 749 (95% CI:0. 699 -0.799)for LSM, 0.642 (95% CI:0. 586 -0. 699) for HBV DNA, and 0. 565 (95% CI:0. 507 -0. 623) for HBsAg, and the combination of LSM, HBV DNA, and HBsAg had a larger AUC of 0. 779 (95% CI:0. 732 -0. 827). Conclusion The levels of LSM, HBV DNA, and HBsAg have a reference value in determining the initiation of antiviral therapy in HBeAg - negative chronic HBV infection patients with ALT=40 U/ L. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

As reported by the world health organization, about 650 thousand people die of liver failure, liver cirrhosis, and hepatocellular carcinoma caused by hepatitis B virus ( HBV) infection every year. Although to a certain extent, the application of interferon and nucleos( t) ide analogues reduces the adverse outcome of chronic hepatitis B (CHB) , so far no effective therapeutic method can eliminate HBV. HBV carriers have a significantly lower incidence rate of adverse outcome than active CHB patients, but they still have the risk of progression to liver cirrhosis and liver cancer. This article discusses the clinical identification and management of HBV carriers, so as to further clarify the features of chronic HBV carriers and related treatment measures in clinical practice. [ABSTRACT FROM AUTHOR]